



CONFIDENTIAL

June 23, 2026

Miguel Martin
Chief Executive Officer & Executive Chairman
Aurora Cannabis Inc.
Via Email: miguel.martin@auroramj.com

Re: Indication of Interest to Explore Strategic Combination

Dear Miguel,

Curaleaf Holdings, Inc. ("Curaleaf") is pleased to submit this non-binding indication of interest to explore a potential business combination with Aurora Cannabis Inc. ("Aurora").

A combination of Curaleaf and Aurora represents a compelling strategic opportunity to create a scaled, diversified, and market-leading global cannabis platform with significant long-term value creation potential. Curaleaf's interest reflects a conviction in the clear industrial logic of combining our respective platforms, capabilities, and geographic footprints.

Curaleaf is contemplating a transaction structured as a combination of both equity consideration and a cash component, designed to align the interests of both shareholder bases. Aurora shareholders would subsequently receive shares in the combined company and thus participate directly in the long-term upside created by the transaction, including the potential value unlock associated with evolving regulatory catalysts in the United States.

We believe that the strategic rationale for a combination is grounded in the following attributes:

1. The combination creates a uniquely scaled global platform, integrating Aurora's EU-GMP cultivation and processing infrastructure, representing nearly 50 tons of annual certified capacity, with Curaleaf's distribution platform in the United States, Europe, and Australia & New Zealand.
2. The businesses are highly complementary, creating immediate diversification across the global medical cannabis markets whilst giving Aurora access to the dominant market share position in the United States, thereby granting exposure to both high-margin and high-growth end markets.
3. Aurora shareholders would benefit from exposure to Curaleaf's U.S. platform and the potential value unlock associated with evolving regulatory catalysts in the United States.
4. There is a clear path to meaningful operational and commercial synergies through asset optimization, procurement efficiencies, SG&A rationalization, and expanded product distribution across a broader platform.
5. Increased scale and diversification are expected to enhance access to capital, improve financial flexibility, and position the combined company to capitalize on future regulatory and market catalysts globally.



To facilitate an efficient and focused process, we would propose entering into a mutually agreed non-disclosure agreement to enable exclusive reciprocal due diligence across operational, financial, legal, and regulatory matters over a period of 30 days. In this context, the parties would work collaboratively and move toward a potential non-binding set of deal terms, including through reciprocal site visits to key cultivation and processing facilities to support detailed operational diligence and integration planning.

The completion of any transaction would be subject to the negotiation and execution of definitive agreements, completion of satisfactory reciprocal confirmatory due diligence, and receipt of all required regulatory approvals and third-party consents.

This letter constitutes a non-binding indication of interest and does not create any legally binding obligations on the part of Curaleaf or Aurora. Any binding commitment would only arise upon execution of definitive agreements approved by the respective boards of directors. Neither party is obligated to pursue or continue discussions or to negotiate or enter into any transaction, and neither party may rely on this letter or on any discussions or negotiations between the parties as creating any obligation, commitment, or expectation that a transaction will be pursued or consummated. Each party reserves the right, in its sole discretion, to terminate discussions at any time and for any reason without liability.

We believe this transaction represents a compelling opportunity for both companies' shareholders and look forward to continuing discussions.

[Signature page to follow.]



Sincerely,

A handwritten signature in black ink, appearing to read "B. Jordan", with a stylized, elongated vertical stroke on the right side.

Boris Jordan
Chief Executive Officer
Curaleaf Holdings, Inc.